AVP-825 Approval Status
- FDA approved: No
- Brand name: AVP-825
- Generic name: sumatriptan
- Company: Avanir Pharmaceuticals, Inc.
- Treatment for: Migraine
AVP-825 (sumatriptan) is an investigational fast-acting, dry-powder intranasal form of sumatriptan in development for the treatment of migraine. In November 2014, the FDA issued a Complete Response Letter for AVP-825 NDA.
FDA Approval Status for AVP-825
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.